July 2012 
Volume 42  Number 7
Pages 9 - 9
  PDF Version Available!

The FDA has issued new warnings about the risks associated with antihypertensive agents containing aliskiren (a renin inhibitor) when given with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). These combinations are contraindicated in patients with diabetes because of the risk of renal impairment, hypotension, and hyperkalemia. In addition, the labeling contains a warning to avoid combining aliskiren with ACEIs or ARBs in patients with renal impairment (glomerular filtration rate < 60 mL/min.).Tell patients taking aliskiren that they shouldn't stop taking the drug without talking to their healthcare provider. Warn them that suddenly stopping the drug may cause hypertension.Source: FDA Drug Safety Communication: New Warning and Contraindication for blood pressure medicines containing aliskiren (Tekuturna). http://www.fda.gov/Drugs/DrugSafety/ucm300889.htm .The FDA recently approved levofloxacin to treat patients with plague, a rare but potentially

Purchase Now !

To purchase this item, follow the instructions below. If you’re not already logged in, be sure to enter your login information below to ensure that your item is saved to your File Drawer after you purchase it.

Not a member? Join now for Free!

1) If you're not already logged in, enter your information below to save this item in your File Drawer for future viewing.

User name:


Forgot your user name or password?
2)  If you have a coupon or promotional code, enter it
here.(If not, just click Continue.

Digital Coupon: (optional)

3)  Click Continue to go to the next screen, where
you'll enter your payment details.

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events